Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Fluorodopa

Другие языки:

Fluorodopa

Подписчиков: 0, рейтинг: 0

Fluorodopa
Clinical data

Trade names	Fluorodopa F18
Other names	6-fluoro-L-DOPA, FDOPA
License data	US DailyMed: Fluorodopa
Routes of administration	Intravenous
ATC code	V09IX05 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid
CAS Number	92812-82-3
PubChem CID	56494
DrugBank	DB13848
ChemSpider	50970
UNII	2C598205QX
KEGG	D04220
ChEBI	CHEBI:49166
ChEMBL	ChEMBL3400972
CompTox Dashboard (EPA)	DTXSID90226257
Chemical and physical data
Formula	C₉H₁₀FNO₄
Molar mass	214.18 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N
InChI InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1 Key:PAXWQORCRCBOCU-RPDRGXCHSA-N

Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).

The most common side effects are injection site pain.

Medical uses

Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).

History

In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).

The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS. The trial was conducted at one clinical site in the United States.